Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies.
Flawless balance sheet and fair value.
Share Price & News
How has Geron's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GERN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GERN underperformed the US Biotechs industry which returned -0.4% over the past year.
Return vs Market: GERN underperformed the US Market which returned -11.9% over the past year.
Price Volatility Vs. Market
How volatile is Geron's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDo Institutions Own Geron Corporation (NASDAQ:GERN) Shares?
1 month ago | Simply Wall StIntroducing Geron (NASDAQ:GERN), The Stock That Slid 58% In The Last Five Years
2 months ago | Simply Wall StIs Geron Corporation's (NASDAQ:GERN) CEO Being Overpaid?
Is Geron undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GERN ($1.07) is trading below our estimate of fair value ($34.04)
Significantly Below Fair Value: GERN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GERN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: GERN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GERN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GERN is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (2.5x).
How is Geron forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GERN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GERN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GERN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GERN's revenue (50.9% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: GERN's revenue (50.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GERN's Return on Equity is forecast to be high in 3 years time
How has Geron performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GERN is currently unprofitable.
Growing Profit Margin: GERN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GERN is unprofitable, and losses have increased over the past 5 years at a rate of -19.8% per year.
Accelerating Growth: Unable to compare GERN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GERN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: GERN has a negative Return on Equity (-50.72%), as it is currently unprofitable.
How is Geron's financial position?
Financial Position Analysis
Short Term Liabilities: GERN's short term assets ($141.6M) exceed its short term liabilities ($28.2M).
Long Term Liabilities: GERN's short term assets ($141.6M) exceed its long term liabilities ($2.2M).
Debt to Equity History and Analysis
Debt Level: GERN is debt free.
Reducing Debt: GERN has not had any debt for past 5 years.
Inventory Level: GERN has a low level of unsold assets or inventory.
Debt Coverage by Assets: GERN's debt is not covered by short term assets (assets are -3.1887286801634E+17x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GERN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: GERN has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of -13.2% each year.
What is Geron's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GERN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate GERN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GERN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GERN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GERN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chip Scarlett (68yo)
Dr. John A. Scarlett, also known as Chip, M.D., has been the Chief Executive Officer of Geron Corporation since joining in September 2011 and its President since January 5, 2012. Dr. Scarlett is Chairman o ...
CEO Compensation Analysis
Compensation vs Market: Chip's total compensation ($USD2.77M) is above average for companies of similar size in the US market ($USD1.47M).
Compensation vs Earnings: Chip's compensation has increased whilst the company is unprofitable.
|CEO, President & Chairman of the Board||8.5yrs||US$2.77m||0.062% $133.7k|
|Executive VP of Finance||7.25yrs||US$1.22m||0.058% $123.9k|
|Executive VP & COO||1.17yrs||US$1.15m||0.0011% $2.4k|
|Executive VP||8.17yrs||US$1.01m||0.0088% $18.9k|
|Executive VP & Chief Business Officer||13.17yrs||US$1.11m||no data|
|Head of Investor Relations & Corporate Communications||no data||no data||no data|
|Vice President of Human Resources||0.75yr||no data||no data|
|Executive VP & Chief Medical Officer||1.17yrs||no data||no data|
|Chief Commercial Officer & Executive VP of Corporate Strategy||0.25yr||no data||no data|
Experienced Management: GERN's management team is considered experienced (4.2 years average tenure).
|CEO, President & Chairman of the Board||8.5yrs||US$2.77m||0.062% $133.7k|
|Lead Independent Director||1.25yrs||US$239.40k||0.019% $41.8k|
|Independent Director||8yrs||US$226.90k||no data|
|Independent Director||1yr||no data||0.0015% $3.2k|
|Independent Director||9.83yrs||US$221.90k||0.048% $103.8k|
|Independent Director||7.5yrs||US$216.90k||0.054% $115.5k|
|Independent Director||1yr||no data||no data|
Experienced Board: GERN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GERN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.7%.
Geron Corporation's company bio, employee growth, exchange listings and data sources
- Name: Geron Corporation
- Ticker: GERN
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$214.369m
- Shares outstanding: 200.34m
- Website: https://www.geron.com
Number of Employees
- Geron Corporation
- 149 Commonwealth Drive
- Suite 2070
- Menlo Park
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GERN||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 1996|
|GON||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 1996|
|0IV3||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jul 1996|
|GON||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Jul 1996|
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/30 01:37|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.